Di Lorenzo G, Morici G, Norrito F, Mansueto P, Melluso M, Purello D'Ambrosio F, Barbagallo Sangiorgi G
Istituto di Medicina Interna e Geriatria, Università degli Studi di Palermo, Italy.
Clin Exp Allergy. 1995 Oct;25(10):951-6. doi: 10.1111/j.1365-2222.1995.tb00397.x.
In atopic asthma there is strong evidence of eosinophils playing an active role in pathogenesis. Some investigations demonstrated that eosinophil cationic protein (ECP) serum levels increased in atopic patients with asthma during pollen season.
The aim of the study was to evaluate the effects of short-term (1 week) beta 2-agonist treatment on lung function and eosinophil activity in asthmatic patients.
We used an open, randomized, cross-over design to compare the effects of salbutamol (200 micrograms q.i.d.) and salmeterol (50 micrograms b.i.d.) on peak expiratory flow rate (PEFR), blood eosinophil count and serum levels of ECP as a measure of eosinophil activity in 20 mild atopic asthmatics.
Morning and evening PEFR values were both significantly higher during salmeterol treatment than during the salbutamol period. Conversely, both morning and evening daily asthma symptom scores were significantly lower during salmeterol treatment compared with those recorded during the salbutamol period. The mean basal eosinophil blood count on salmeterol treatment (601 +/- 189 mm3) was not higher than the mean count on salbutamol treatment (612 +/- 204 mm3). After both treatments the mean eosinophil blood counts were unchanged (619 +/- 189 mm3 and 576 +/- 212 mm3, respectively). No significant differences in blood eosinophil counts were observed between or within treatments at any time. No significant difference was observed in baseline mean ECP serum concentration (43.8 +/- 26.3 micrograms/L on salmeterol treatment and 41.7 +/- 29.8 micrograms/L on salbutamol treatment, respectively). After salmeterol treatment the mean ECP serum concentration had fallen significantly to 20.9 +/- 18.6 micrograms/L (P < 0.01), whereas after salbutamol treatment it was unchanged (42.0 +/- 25.1 micrograms/L). Salmeterol treatment produced a decrease in ECP serum levels without any changes in blood eosinophil count.
This study demonstrates that salmeterol affords a significant improvement in asthma control during the pollen season, measured by both subjective and objective parameters, compared with salbutamol. This greater efficacy may be related to inhibition of eosinophil degranulation during the pollen season.
在特应性哮喘中,有充分证据表明嗜酸性粒细胞在发病机制中发挥积极作用。一些研究表明,在花粉季节,患有哮喘的特应性患者血清嗜酸性粒细胞阳离子蛋白(ECP)水平会升高。
本研究旨在评估短期(1周)β2激动剂治疗对哮喘患者肺功能和嗜酸性粒细胞活性的影响。
我们采用开放、随机、交叉设计,比较沙丁胺醇(200微克,每日4次)和沙美特罗(50微克,每日2次)对20例轻度特应性哮喘患者的呼气峰值流速(PEFR)、血液嗜酸性粒细胞计数以及作为嗜酸性粒细胞活性指标的血清ECP水平的影响。
沙美特罗治疗期间早晚的PEFR值均显著高于沙丁胺醇治疗期。相反,与沙丁胺醇治疗期记录的相比,沙美特罗治疗期间早晚的每日哮喘症状评分均显著更低。沙美特罗治疗时的平均基础嗜酸性粒细胞血液计数(601±189/mm³)不高于沙丁胺醇治疗时的平均计数(612±204/mm³)。两种治疗后,平均嗜酸性粒细胞血液计数均未改变(分别为619±189/mm³和576±212/mm³)。在任何时间,治疗组间或组内的血液嗜酸性粒细胞计数均未观察到显著差异。沙丁胺醇治疗时的基线平均ECP血清浓度(分别为43.8±26.3微克/升和41.7±29.8微克/升)未观察到显著差异。沙美特罗治疗后,平均ECP血清浓度显著降至20.9±18.6微克/升(P<0.01),而沙丁胺醇治疗后未改变(42.0±25.1微克/升)。沙美特罗治疗使ECP血清水平降低,而血液嗜酸性粒细胞计数无任何变化。
本研究表明,与沙丁胺醇相比,沙美特罗在花粉季节通过主观和客观参数衡量,能显著改善哮喘控制。这种更高的疗效可能与在花粉季节抑制嗜酸性粒细胞脱颗粒有关。